Targeting lethal minimal residual disease in small cell lung cancer

Jyoti Dinker Patel, Lee M. Krug*, Christopher G. Azzoli, Jorge Gomez, Mark G. Kris, Vincent A. Miller

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

In the last three decades, treatment for small cell lung cancer has improved with advances in chemotherapy and radiotherapy. Almost all patients respond initially to standard chemotherapy, and some patients with limited stage disease are cured with the combination of chemotherapy and thoracic irradiation. Nonetheless, the majority of patients will experience lethal relapse from chemotherapy-resistant micrometastatic disease, and this has resulted in poor long-term survival for most patients. Addressing the problem of relapse requires unique approaches to eliminating minimal residual disease. This review will focus on the detection of minimal residual disease as well as strategies with which to treat it, including matrix metalloproteinase inhibitors, tyrosine kinase inhibitors, and vaccine therapy.

Original languageEnglish (US)
Pages (from-to)79-85
Number of pages7
JournalSeminars in Oncology
Volume30
Issue number1
DOIs
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Targeting lethal minimal residual disease in small cell lung cancer'. Together they form a unique fingerprint.

Cite this